Abstract： Objective： To observe the effect of Kunxian Capsules combined with Valsartan on renal interstitial fibrosis，immune-inflammatory factors and hemorheology in patients with diabetic nephropathy. Methods： A total of 120 patients with diabetic nephropathy admitted to the Nephrology Department of Nanyang Central Hospital from March 2022 to March 2023 were randomly divided into the Kunxian Capsules group and the Valsartan group， with 60 patients in each group. The Valsartan group received Valsartan treatment orally， and the Kunxian Capsules group received Kunxian Capsules in addition to the Valsartan group treatment plan. Both groups were treated continuously for two months. The renal interstitial fibrosis indicators [transforming growth factor- β1 (TGF- β1)， vascular endothelial growth factor (VEGF)， and angiotensin Ⅱ(Ang Ⅱ)]，inflammatory factors [C-reactive protein (CRP)，tumor necrosis factor-α (TNF-α)， and interleukin-6 (IL-6)]，hemorheological indicators (red blood cell aggregation indexes，plasma viscosity， low-shear viscosity， and high-shear viscosity)， traditional Chinese medicine syndrome scores， and clinical effects were observed and recorded in the two groups. Results：After treatment，the levels of CRP， TNF-α，IL-1，α-SMA，Ang Ⅱ，and TGF-β1，and traditional Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment， with differences being significant (P＜0.05)； the values of the above indicators in the Kunxian Capsules group were lower than those in the Valsartan group， with differences being significant (P＜0.05). After treatment， the red blood cell aggregation indexes， plasma viscosity， low-shear viscosity， and high-shear viscosity in the two groups were decreased when compared with those before treatment， and the values of the above indicators in the Kunxian Capsules group were lower than those in the Valsartan group， with differences being significant (P＜0.05). The total effective rate in the Kunxian Capsules group was 93.33%，and 80.00% in the Valsartan group， with the difference being significant (P＜0.05). Conclusion： Kunxian Capsules combined with Valsartan can effectively inhibit renal parenchymal fibrosis and inflammatory reactions， reduce blood viscosity，and improve the quality of life of patients with diabetic nephropathy.